We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-3.9%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.47B
AUM Growth
-$289M
Cap. Flow
-$262M
Cap. Flow %
-10.6%
Top 10 Hldgs %
61.17%
Holding
110
New
16
Increased
30
Reduced
10
Closed
25

Top Buys

Rank Stock Value
1
AMZN icon
Amazon
AMZN
+$15.8M
2
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
+$14.7M
3
INCY icon
Incyte
INCY
+$14.3M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$11.2M
5
TEX icon
Terex
TEX
+$6.1M

Top Sells

Rank Stock Value
1
FURX
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
+$78.4M
2
AMGN icon
Amgen
AMGN
+$17.4M
3
DG icon
Dollar General
DG
+$13.9M
4
MJN
Mead Johnson Nutrition Company
MJN
+$12.5M
5
BRFS
BRF SA
BRFS
+$10.1M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 25.19%
2 Healthcare 24.42%
3 Financials 1.12%
4 Industrials 0.54%
5 Technology 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WW
1
DELISTED
WW International
WW
$580M 23.44%
28,749,089
– –
LXRX icon
2
Lexicon Pharmaceuticals
LXRX
$1.03B
$408M 16.49%
36,196,019
– –
SPY icon
3
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$778B
$196M 7.91%
1,000,000
+300,000
+43% +$57M
MRK icon
4
CALL
Merck
MRK
$323B
$75.2M 3.04%
1,362,400
– –
MET icon
5
CALL
MetLife
MET
$62.6B
$50M 2.02%
1,009,800
+448,800
+80% +$21M
AMGN icon
6
CALL
Amgen
AMGN
$213B
$47.3M 1.91%
400,000
+300,000
+300% +$34.7M
AUXL
7
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
$40.4M 1.63%
2,015,000
+640,000
+47% +$14.7M
GE icon
8
CALL
GE Aerospace
GE
$368B
$39.4M 1.59%
312,993
– –
BMY icon
9
CALL
Bristol-Myers Squibb
BMY
$130B
$38.8M 1.57%
800,000
+300,000
+60% +$14.8M
BAC icon
10
CALL
Bank of America
BAC
$434B
$38.4M 1.55%
2,500,000
+1,500,000
+150% +$23.3M
GOOG icon
11
CALL
Alphabet (Google) Class C
GOOG
$4.05T
$37.5M 1.52%
1,303,569
-503,178
-28% -$13.7M
ITB icon
12
CALL
iShares US Home Construction ETF
ITB
$2.36B
$37.2M 1.5%
1,500,000
+750,000
+100% +$17.9M
TEVA icon
13
CALL
Teva Pharmaceuticals
TEVA
$40B
$36.7M 1.48%
700,000
+100,000
+17% +$5.11M
CIT
14
CALL
DELISTED
CIT Group Inc.
CIT
$34.3M 1.39%
750,000
– –
BMRN icon
15
BioMarin Pharmaceuticals
BMRN
$12B
$32.7M 1.32%
525,000
– –
BIIB icon
16
CALL
Biogen
BIIB
$32B
$31.5M 1.27%
100,000
+25,000
+33% +$7.52M
GM icon
17
CALL
General Motors
GM
$82.4B
$30.9M 1.25%
850,000
-400,000
-32% -$13.9M
JPM icon
18
CALL
JPMorgan Chase
JPM
$930B
$28.8M 1.16%
500,000
+250,000
+100% +$14.1M
AIG icon
19
CALL
American International
AIG
$42.6B
$27.3M 1.1%
500,000
-350,000
-41% -$18.5M
BMRN icon
20
CALL
BioMarin Pharmaceuticals
BMRN
$12B
$24.9M 1.01%
400,000
+200,000
+100% +$12.1M
PCYC
21
DELISTED
PHARMACYCLICS INC
PCYC
$24.2M 0.98%
270,000
+60,000
+29% +$5.63M
IWM icon
22
CALL
iShares Russell 2000 ETF
IWM
$79.8B
$23.8M 0.96%
+200,000
New +$22.7M
C icon
23
CALL
Citigroup
C
$217B
$23.6M 0.95%
500,000
-1,350,000
-73% -$64.2M
AUXL
24
CALL
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
$22.1M 0.89%
1,100,000
+200,000
+22% +$4.59M
INCY icon
25
Incyte
INCY
$25.6B
$21.4M 0.87%
380,000
+280,000
+280% +$14.3M
1
2 3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q2 2014 Portfolio in Review

As of Q2 2014, Artal Group held 110 positions worth $2.47B, down 10% from $2.76B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Artal Group withdrew a net $262M in Q2 2014, closing 25 positions and reducing 10 holdings. Its most notable exit was FURIEX PHARMACEUTICALS INC COM STK (DE), an estimated $78.4M position sold in full.

By sector, the portfolio is most concentrated in Consumer Discretionary at 25% of assets, up from 23% a quarter earlier, followed by Healthcare and Financials.

Against the trend, Artal Group opened a new position in Amazon worth $16.2M.

  • Artal Group's largest Q2 2014 buy was Amazon: 1,000,000 shares worth $16.2M.
  • Artal Group added most to AUXILIUM PHARAMCEUTICALS INC in Q2 2014, an estimated $14.7M increase.
  • Artal Group's biggest Q2 2014 reduction was Ralph Lauren, cutting an estimated $3.85M.
  • Artal Group fully exited FURIEX PHARMACEUTICALS INC COM STK (DE) in Q2 2014, selling an estimated $78.4M.
  • Artal Group's ten largest holdings make up 61% of its $2.47B portfolio in Q2 2014.
  • Artal Group opened 16 new positions and closed 25 in Q2 2014.
  • Artal Group's portfolio value fell 10% quarter-over-quarter to $2.47B.

Based on Artal Group's 13F filing for Q2 2014, filed 14 Aug 2014.